Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display

Journal home page for Cell ReportsShow moreAdd to Mendeleyhttps://doi.org/10.1016/j.celrep.2022.110348Get rights and content

open access

Highlights (3 to 4 main points)o

Broadly-reactive neutralizing antibodies (nAbs) may overcome SARS-CoV-2 variant escape

o

mRNA display is used to rapidly identify SARS-CoV-2 spike (S) protein-directed nAbs

o

Structural studies reveal distinct binding modes for several identified antibodies

o

An engineered nAb sustains binding to variant Gamma E484K and Delta L452R spike

Summary

The increasing prevalence of SARS-CoV-2 variants with the ability to escape existing humoral protection conferred by previous infection and/or immunization necessitates the discovery of broadly-reactive neutralizing antibodies (nAbs). Utilizing mRNA display, we identify a set of antibodies against SARS-CoV-2 spike (S) proteins and characterize the structures of nAbs that recognize epitopes in the S1 subunit of the S glycoprotein. These structural studies reveal distinct binding modes for several antibodies, including targeting of rare cryptic epitopes in the receptor-binding domain (RBD) of S that interacts with angiotensin-converting enzyme 2 (ACE2) to initiate infection, as well as the S1 subdomain 1. Further, we engineer a potent ACE2-blocking nAb to sustain binding to S RBD with the E484K and L452R substitutions found in multiple SARS-CoV-2 variants. We demonstrate that mRNA display is a promising approach for the rapid identification of nAbs that can be used in combination to combat emerging SARS-CoV-2 variants.

Graphical Abstract

Recommended articlesCiting articles (0)

(C) 2022 The Authors.

Recommended articles

No articles found.

Citing articles

Komentar

Postingan populer dari blog ini

Distilled White Vinegar And Mold

Ashford Concrete Sealer

News24com SA ambassador and family other diplomats flee Ukraine in convoy